Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1758-9193
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease ; volume:14 ; number:1 ; day:24 ; month:9 ; year:2022 ; pages:1-13 ; date:12.2022
Alzheimer's research & therapy ; 14, Heft 1 (24.9.2022), 1-13, 12.2022

Urheber
Rubinski, Anna
Franzmeier, Nicolai
Dewenter, Anna
Luan, Ying
Smith, Ruben
Strandberg, Olof
Ossenkoppele, Rik
Dichgans, Martin
Hansson, Oskar
Ewers, Michael
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s13195-022-01074-9
URN
urn:nbn:de:101:1-2022121221100711562703
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:26 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

Ähnliche Objekte (12)

[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case

[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Fluid biomarkers in Alzheimer’s disease – current concepts

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease

Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study

Blood‐based biomarkers for Alzheimer's disease

Blood‐based biomarkers for Alzheimer's disease

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume

Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Verbundene Objekte